FOXO4-DRI · 10 mg
Published- batch · LOT
- B-2026-FOXO4DRI-10-001
- Laboratory
- Uzorak
- purity
- 99.97%
- Test date
- 27.07.2026
Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
FOXO4-DRI — a D-retro-inverso peptide that disrupts the FOXO4–p53 interaction, studied as a senolytic in cellular-senescence models. Lyophilized, HPLC testing on every batch. Research use only (RUO).
Selected size: 10 mg
10 mg analysis published
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (3 consecutive days) | 0.5–1 mg subcutaneously per day | Starting dose |
| Main cycle (3 consecutive days) | 2–2.5 mg subcutaneously per day | Increase if needed |
| Cycle ceiling; cycle repeated 2–3x per year | up to 5 mg subcutaneously per day | Maximum in this schedule |
Certificates shown: 1
Share your experience
No reviews yet. Tell others what you think of this product.
FOXO4-DRI is a synthetic senolytic peptide built on a D-retro-inverso scaffold. It was designed to disrupt the interaction between the FOXO4 transcription factor and the tumour-suppressor p53 — the survival mechanism that senescent ("zombie") cells rely on — freeing p53 to trigger apoptosis selectively in those cells.
Interest in FOXO4-DRI stems from a landmark 2017 study in Cell, where the peptide cleared senescent cells and was associated with restored fitness, fur density and renal function in aged mice, and from later in vitro and rodent work across chondrocyte, fibroblast, endothelial and Leydig-cell models. It sits at the research frontier of "senescent-cell clearance" and remains a rare, specialist reagent rather than a mass-market peptide.
